Tagged with BI

China A roundup of some ot the biggest stories coming out of China’s biopharma industry: Chinese pharma shifts to local reagent suppliers; WuXi Biologics launches new stable cell line platform; Fosun and Expedition Therapeutics ink respiratory licensing deal, and GSK lands USD 500 million 12-drug agreement with Hengrui Pharma.   China…

Switzerland Jorge Santos da Silva is the CEO and Co-founder of MoonLake Immunotherapeutics, a Swiss biotech company known for its bold approach to drug development. With a background in neuroscience, a decade in academic research, and over 15 years at McKinsey, where he was a Senior Partner, advising pharma and biotech…

Denmark Morten Graugaard, former partner at Novo Holdings A/S, a global life science investment fund, became CEO of Orbis Medicine in February 2025. Drawing on his deep experience in life sciences and venture capital, he has led the company to raise EUR 116 million in funding, positioning Orbis as a pioneer…

Switzerland Pharmaceutical manufacturing is evolving into a strategic pillar of competitiveness, shaped by modular design, digital integration, and a growing focus on long-term efficiency. Bilfinger, through its Technology segment, is playing a central role in this transformation, supporting clients across biopharma, energy transition, and nuclear with scalable, future-ready solutions. In this…

Colombia Clara Isabel Rodríguez, Executive Director of the Colombian Association of the Pharmaceutical Industry (ASCIF), shares her journey from public sector leadership to industry advocacy. With deep experience in health regulation and public administration, Rodríguez reflects on Colombia’s pharma landscape, the challenges of ongoing health reform, and why local manufacturing is…

China Chinese biotech is booming, led by a generation of pioneering individuals at the forefront of science and business.   A country once best known as a low-cost manufacturing destination for ‘me-too’ copycat medicines now accounts for over 28 percent of the global drug development pipeline. Western companies approaching patent cliffs…

China Dr Ben Zhao, Chief Executive Officer and co-founder of Haichang Biotechnology (HCBio, Haichang), represents a new paradigm in pharmaceutical innovation, bridging regulatory expertise with entrepreneurial vision. Having transitioned from a distinguished career at the FDA to establishing one of the most promising lipid nanoparticle delivery platforms in the industry, he…

Puerto Rico Long celebrated for its world-class pharmaceutical and medical device manufacturing, Puerto Rico is now leveraging this strong foundation to nurture a new era of research and development. Rather than shifting away from production, the island is integrating R&D directly into its manufacturing operations — from pilot plants and small-scale prototyping…

Europe Pharma and biotech companies are doubling down on innovation and, often, outsourcing just about everything else. That shift has turned contract development and manufacturing organisations (CDMOs) into critical partners, not just service providers. The sector is booming, but pressure is building fast: demand is surging, capacity is stretched, and new…

UK The latest from UK pharma, including teething troubles and industry pushback for the country’s new life sciences strategy; Sanofi snapping up UK vaccines outfit Vicebio for USD 1.6 billion; and why AstraZeneca’s latest US manufacturing investment does little to ease fears that the British firm might choose to relocate across…

Global Writing in the July 2025 edition of DIA Global Forum, Samantha Holmes, Fiona Adshead, and Keith Moore of the Sustainable Healthcare Coalition explore how cross-sector partnerships are advancing environmental sustainability in healthcare. They highlight real-world examples—from GSK’s Carbon Neutral Lab to the SMI Health Systems Task Force; showing how collaboration…

France The top 10 companies in the French retail generics market for 2024 according to Smart Pharma Consulting’s insights on the French pharma market. Last year, Viatris and Biogaran generated more than EUR 2.9 billion in sales and, taken together, represented over half of the total French retail generic market in…